Search for a trial

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation.

Primary ObjectiveEstimate the proportion of subjects fulfilling criteria for symptomatic remission (as defined by Andreasen et al.)* following a transition to 12 months* treatment with flexible-dose PP3M in subjects with schizophrenia previously…

A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E E4 Noncarriers and Participated in Study 3133K1-3000-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives: Efficacy. To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using…

A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers and Participated in Study 3133K1-3001-WW

Primary objectives: To evaluate the long-term safety and tolerability of IV administered bapineuzumab in subjects with AD.Secundary objectives:To explore the long-term efficacy of IV administered bapineuzumab in subjects with AD, using the following…

Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in…

A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated with oral or long-acting injectable antipsychotics.

Primary ObjectivesThe primary objective is to explore the tolerability, safety and treatment response (maintained/improved efficacy), based on total Positive and Negative Syndrome Scale (PANSS) score, of a transition to flexibly dosed paliperidone…

A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in Study SPD503-315 or SPD503-316

The primary objective of this study is to provide access to SPD503 following participation in SPD503-315 or SPD503-316. The primary outcome of this study is to evaluate the long-term safety of SPD503. The evaluation of safety will be based on the…

An open label study with objective sleepregistration on the effects of Doxazosin as treatment for PTSD, especially for sleep disturbance

To evaluate the effect on sleep and ptsd of the drug Doxazosin Retard in patients with PTSD who also have sleep problems.

A Phase 4, Open-label, Multicentre, 2-Year Safety Study of
Lisdexamfetamine Dimesylate in Children and Adolescents Aged
6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

Primary: The primary objective of this study is to evaluate the long-term safety of SPD489 administered as adaily morning dose (30, 50, and 70mg) in the treatment of children and adolescents (6-17 years of ageinclusive at the time of consent in this…

Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer*s Type.

Safety-evaluation in case of long term daily usage of MPC-7869. In this Open Label Study , with regard to the safety of MPC-7869, attention will be paid to the amount of AE*s, the physical examinations of subjects, the research of vital functions,…

An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia

The aim of this study is to collect data in a structured way in order to explore the tolerability, safety and efficacy of paliperiode ER with treatment schedules which will be used in future clinical practice.

Internet-based self-help for Insomnia: Factors that are associated with succes of the intervention

The object of this study is to determine variables associated with therapy-success of a cognitive behavioral self help intervention for insomnia.

Pharmacokinetics of escalating doses of clonidine in ICU patients

Primary objective:Plasma levels of clonidine, in order to describe pharmacokinetic and pharmacodynamic properties of intravenous clonidine in critically ill ventilated ICU patients.Secondary objectives are: * to evaluate the effect of a 3-hr loading…

Glutamatergic medication in the treatment of Obsessive Compulsive Disorder (OCD) and
Autism Spectrum Disorder (ASD)

The Primary objective is: 1) To investigate clinical effectiveness of the glutamatergic compound memantine in paediatric patients with: - Obessive-Compulsive Disorder (OCD) GOAT-1 - Autism Spectrum Disorder (ASD) GOAT-2 with respect to symptoms of…

A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder

The primary objective of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with OCD who have had an inadequate response to standard of care (SOC) treatment for OCD and as defined in the…

Imagery Rescripting for Obsessive Compulsive Disorder, Body Dysmorphic Disorder and Early Psychosis: a Multiple-Baseline Single-Case Experimental Design.

Primary Objective: To investigate the effectiveness of imagery rescripting on factors presumed to underlie the disorder, according to schema theory, and on OCD and BDD symptoms and psychosis. Primary objective is the course of schema or core beliefs…

Deep brain stimulation for obsessive-compulsive disorder

Establishing efficacy and safety of the electrodes and implantable pulse generators (IPGs), which are used for deep brain stimulation (DBS) in patients with obsessive-compulsive disorder (OCD).